OptimizeRx Corporation OPRX
7.84 USD -1.11 (-12.46%)
Nov 12, 2026, 3:45 PM EST
6.33 Day range 7.90
4.54 52-week range 16.37
- YTD
- -36.09%
- 1 year
- -51.49%
News
benzinga.com Lake Street Maintains Buy on OptimizeRx, Lowers Price Target to $10 Lake Street analyst Eric Martinuzzi maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $11 to $10.
benzinga.com These Analysts Cut Their Forecasts On OptimizeRx After Q3 Results OptimizeRx Corporation (NASDAQ:OPRX) reported upbeat earnings for the third quarter, but lowered its sales guidance on Wednesday.
benzinga.com These Analysts Cut Their Forecasts On OptimizeRx After Q3 Results OptimizeRx beat Q3 earnings and sales estimates but cut FY2026 revenue guidance; shares fell 17.3% as analysts lowered price targets.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 73.5% to $5.01 during Thursday's regular session. enGene Therapeutics (NASDAQ:ENGN) stock rose 29.37% to $2.33. The company's market…
benzinga.com B. Riley Securities Reiterates Buy on OptimizeRx, Lowers Price Target to $10.5 B. Riley Securities analyst Josh Nichols reiterates OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $11 to $10.5.- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Addex Therapeutics (NASDAQ:ADXN) stock rose 74.0% to $5.03 during Thursday's pre-market session. ZeroStack (NASDAQ:ZSTK) stock increased by 11.56% to $2.99. The market value of their…
- benzinga.com Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $11 Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $12 to $11.
benzinga.com Why Tetra Tech Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket Tetra Tech shares jumped 8.5% after beating Q4 estimates; Children's Place surged 302%, while Wheeler REIT fell 35.3% premarket.
benzinga.com OptimizeRx Shares Tumble 20% After-Hours: Here's Why OptimizeRx shares tumble 20% after-hours after earnings beat estimates despite lower 2026 revenue guidance.
seekingalpha.com OptimizeRx Corporation (OPRX) Q3 2026 Earnings Call Transcript OptimizeRx Corporation (OPRX) Q3 2026 Earnings Call Transcript
marketbeat.com What OptimizeRx (OPRX) Said on Its Q3 Earnings Call OptimizeRx NASDAQ: OPRX lowered its 2026 revenue outlook after third-quarter sales fell 17%, even as cost reductions and a favorable product mix helped the healthcare marketing technology company…
zacks.com OptimizeRx Corp. (OPRX) Q3 Earnings and Revenues Beat Estimates OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.2 per share a year ago.
benzinga.com OptimizeRx Q3 2026 Earnings Call Transcript OptimizeRx (NASDAQ:OPRX) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Can Fite Biopharma (AMEX:CANF) stock rose 7.1% to $1.66 during Wednesday's after-market session. The market value of their outstanding shares is at $3.5 million. iTonic Holdings (NASDAQ:ITOC)…
benzinga.com OptimizeRx Q3 Adj. EPS $0.20 Beats $0.17 Estimate, Sales $21.615M Beat $21.188M Estimate OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.17 by 17.65 percent. This is unchanged from the same period last year. The…
benzinga.com OptimizeRx Lowers FY2026 Sales Guidance from $95.000M-$100.000M to $87.000M-$93.000M vs $96.230M Est OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $95.000 million-$100.000 million to $87.000 million-$93.000 million vs $96.230 million estimate.
globenewswire.com OptimizeRx Reports Third Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance WALTHAM, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and…- benzinga.com B. Riley Securities Maintains Buy on OptimizeRx, Raises Price Target to $11 B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and raises the price target from $10 to $11.
- benzinga.com Citizens Maintains Market Outperform on OptimizeRx, Raises Price Target to $11 Citizens analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price target from $9 to $11.
benzinga.com OptimizeRx Affirms FY2026 Sales Guidance of $95.000M-$100.000M vs $97.427M Est OptimizeRx (NASDAQ:OPRX) affirms FY2026 sales outlook from $95.000 million-$100.000 million to $95.000 million-$100.000 million vs $97.427 million estimate.
benzinga.com OptimizeRx Q2 Adj. EPS $0.16 Beats $0.12 Estimate, Sales $20.504M Beat $20.204M Estimate OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.12 by 33.33 percent. This is a 33.33 percent decrease over earnings of $0.24…
benzinga.com OptimizeRx Rolls Out CopayCue To Provide Enhanced Brand Savings For Physicians OptimizeRx Corp. (the "Company") (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at…- benzinga.com OptimizeRx's Electronic Health Record Network Integrated By DeepIntent OptimizeRx Corp. (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare providers (HCPs) and patients at the most important…
- benzinga.com Lake Street Maintains Buy on OptimizeRx, Lowers Price Target to $11 Lake Street analyst Eric Martinuzzi maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $20 to $11.
- benzinga.com B. Riley Securities Maintains Buy on OptimizeRx, Lowers Price Target to $10 B. Riley Securities analyst Anderson Schock maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $11 to $10.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com Stephens & Co. Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $7 Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and lowers the price target from $10 to $7.
- benzinga.com Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $14 Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $17 to $14.
- benzinga.com OptimizeRx Reports Q1 2026 Results: Full Earnings Call Transcript
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com OptimizeRx Lowers FY2026 Sales Guidance from $109.000M-$114.000M to $95.000M-$100.000M vs $111.438M Est OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $109.000 million-$114.000 million to $95.000 million-$100.000 million vs $111.438 million estimate.- benzinga.com OptimizeRx Q1 Adj. EPS $0.14 Beats $0.00 Estimate, Sales $19.844M Beat $18.353M Estimate OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. This is a 75 percent increase over earnings of $0.08…
benzinga.com Earnings Scheduled For May 12, 2026 - benzinga.com OptimizeRx Launches New Programmatic Connection Point Between OptimizeRx's Proprietary EHR Network And DSPs OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare providers (HCPs) and patients at the…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Lake Street Maintains Buy on OptimizeRx, Lowers Price Target to $20 Lake Street analyst Eric Martinuzzi maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $24 to $20.
benzinga.com OptimizeRx Warns Of Volatility From 'Most Favored Nation' Pricing Uncertainty OptimizeRx CEO warns of increased market volatility and uncertainty around MFN pricing. Lower 2026 forecasts due to cautious spending.
benzinga.com Assessing OptimizeRx: Insights From 4 Financial Analysts 
benzinga.com Roth Capital Maintains Buy on OptimizeRx, Lowers Price Target to $18 Roth Capital analyst Richard Baldry maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $32 to $18.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com B. Riley Securities Reiterates Buy on OptimizeRx, Lowers Price Target to $11 B. Riley Securities analyst Anderson Schock reiterates OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $28 to $11.
- benzinga.com Stephens & Co. Maintains Equal-Weight on OptimizeRx, Lowers Price Target to $10 Stephens & Co. analyst Jeff Garro maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and lowers the price target from $17 to $10.
- benzinga.com Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $17 Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $21 to $17.
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com OptimizeRx Lowers FY2026 Sales Guidance from $118.000M-$124.000M to $109.000M-$114.000M OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $118.000 million-$124.000 million to $109.000 million-$114.000 million.
- benzinga.com OptimizeRx Q4 Adj. EPS $0.51 Beats $0.23 Estimate, Sales $32.200M Beat $31.100M Estimate OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.23 by 124.67 percent. This is a 70 percent increase over earnings of $0.30 per…
- benzinga.com Earnings Scheduled For March 5, 2026
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com OptimizeRx Partners With Lamar Advertising To Revolutionize OOH Advertising For Pharmaceutical And Healthcare Brands Strategic Partnership Combines OptimizeRx's Patented Micro-Neighborhood® Targeting Data with Lamar's Vast Nationwide OOH Network to Strengthen OOH Media for Healthcare MarketingWALTHAM, Mass., Sept.…